Actinium Pharmaceuticals, Inc.

254 articles with Actinium Pharmaceuticals, Inc.

• Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy

  10/21/2020

  NIH grant to support first of its kind clinical trial to use Antibody Radio-Conjugate for targeted conditioning prior to CAR T-cell therapy in patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma

• Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform

  10/14/2020

  Actinium Pharmaceuticals, Inc. announced the launch of its new research and development lab facility in New York City.

• Actinium Pharmaceuticals, Inc. Announces Clinical Trial Site Expansion in its Multi-Center Phase 1/2 Actimab-A Venetoclax Combination Trial

  10/6/2020

  Actinium Pharmaceuticals, Inc. announced that the University of Louisville and the Ochsner Clinic in New Orleans, Louisiana are now active trial sites in its Phase 1/2 Actimab-A venetoclax combination trial for patients with Relapsed or Refractory Acute Myeloid Leukemia age 18 and above.

• Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in Relapsed/Refractory AML Patients

  9/23/2020

  Combination trial, led by UCLA Medical Center and Principal Investigator Gary Shiller, MD, supported by mechanistic rationale and demonstrated synergy of combining venetoclax with targeted radiation from Actimab-A in preclinical studies

• Actinium Pharmaceuticals Announces Successful Completion of Planned Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed/Refractory AML at Medical College of Wisconsin

  9/14/2020

  - Trial results including data from third dose cohort to be presented by year end; - Second dose cohort demonstrated 86% complete remission rate with 71% of patients achieving negative minimal residual disease status, as previously reported

• Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual H.C. Wainwright Global Investor Conference

  9/10/2020

   Actinium Pharmaceuticals, Inc.   (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its Chairman and Chief Executive Officer Sandesh Seth will be presenting at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14 th at 2:00 PM EST .

• Actinium Pharmaceuticals, Inc. Announces Reverse Stock Split - Aug 10, 2020

  8/10/2020

  Actinium Pharmaceuticals, Inc. announced that its Board of Directors approved a 1-for-30 reverse split of its issued and outstanding common stock that will become effective after trading closes on August 10, 2020.

• Actinium Pharmaceuticals, Inc. Announces Closing of $25.0 Million Public Offering

  6/19/2020

  Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced the closing of its previously announced public offering of 76,923,077 shares of its common stock (or common stock equivalents in lieu thereof) at a price to the public of $0.325 per share of common stock (or common stock equivalent

• Actinium Pharmaceuticals, Inc. Announces Pricing of $25.0 Million Public Offering

  6/17/2020

  Actinium Pharmaceuticals, Inc. announced the pricing of its previously announced public offering of 76,923,077 shares of its common stock at a price to the public of $0.325 per share of common stock.

• Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering - June 16, 2020

  6/16/2020

  Actinium Pharmaceuticals, Inc. announced that it intends to offer and sell shares of its common stock in a public offering.

• Actinium Pharmaceuticals, Inc. Announces Closing of $31.6 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares

  4/24/2020

  Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced the closing of the Company's previously announced underwritten public offering of 210,833,334 shares of common stock (or common stock equivalents in lieu thereof) at an effective public offering price of $0.15 per share of common stock

• Actinium Pharmaceuticals, Inc. Announces Pricing of $27.5 Million Public Offering

  4/22/2020

  Actinium Pharmaceuticals, Inc. announced the pricing of the Company's previously announced underwritten public offering of 183,333,334 shares of common stock at a public offering price of $0.15 per share of common stock.

• Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering

  4/21/2020

  Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) in an underwritten public offering

• Actinium Provides Update on Iomab-B SIERRA Trial and Expected Topline Results from Ad Hoc Analysis in 2020

  4/16/2020

  Single ad hoc interim analysis for SIERRA trial to be exercised at the Company's discretion in Q2 2020, making topline data results available in Q4 2020

• Actinium Pharmaceuticals Announces First Patient Treated in Third and Final Dose Cohort of Actimab-A CLAG-M Combination Phase 1 Trial in Acute Myeloid Leukemia

  3/5/2020

  Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium") today announced that the first patient has begun treatment in the third and final cohort of the Actimab-A CLAG-M combination trial.

• Actinium Announces Actimab-A Plus 7+3 Combination Trial for Newly Diagnosed Acute Myeloid Leukemia Patients

  2/26/2020

  - Study builds on recent Actimab-A plus CLAG-M combination trial results showing an 86% remission rate with 71% MRD negative rate in CD33 positive patients with relapsed or refractory AML - Combination trial with 7+3 standard of care regimen in intermediate and high-risk patients expands potential of Actimab-A into large segment of AML - Trial to be led by Dr. Joseph Jurcic, M.D., Director of Hematologic Malignancies at Columbia University Irving Medical Center

• Actinium Presents Positive Findings from Mid-Point Analysis of Pivotal SIERRA Trial of Iomab-B at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT)

  2/21/2020

  - Substantially lower rates of febrile neutropenia and sepsis in patients receiving Iomab-B compared to patients receiving salvage chemotherapy in the control arm

• Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting; Phase 3 SIERRA Trial Preliminary Results Selected for Oral Presentation

  2/13/2020

  77% of all participating patients who are typically considered ineligible have received a bone marrow transplant in the SIERRA trial, the only randomized Phase 3 trial to offer potentially curative allogeneic transplant to older patients with active, relapsed or refractory AML

• Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference

  2/5/2020

  - Presentation scheduled for Tuesday, February 11th at 10:15 am ET

• Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma

  1/13/2020

  Trial will replace currently used chemotherapy conditioning with apamistamab-I-131, Actinium's targeted conditioning ARC, to selectively eliminate lymphoma cancer cells and stem cells to enable engraftment of stem cell gene therapy